Safety and Tolerability of the Vaginal Gel PRO 2000/5
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party)
National Institute of Allergy and Infectious Diseases (NIAID)
First received: September 11, 2000
Last updated: July 29, 2008
Last Verified: June 2003
History of Changes
The purpose of this study is to determine whether the vaginal gel PRO 2000/5 causes
irritation when used daily.
Studies have shown PRO 2000/5 is safe and well tolerated as a vaginal gel in healthy women who are not sexually active. However, it was not determined what side effects to skin in the vaginal area there might be in sexually active women.
Drug : PRO 2000
Primary Purpose: Prevention
|Official Title:||A Phase I Multicenter Dose Escalation Safety and Acceptability Study of the Investigational Vaginal Microbicide Agent PRO 2000/5 Gel (P)|
Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):
Vaginal microbicides are designed to inhibit the sexual transmission of HIV-1 and other
disease pathogens. Two Phase I clinical trials were conducted to evaluate the safety and
tolerance of the gel, PRO 2000/5, in sexually abstinent volunteers. Both demonstrated that
multiple application of the gel was safe and well tolerated in healthy, sexually abstinent
women but no clear association between the use of the gel and epithelial disruption was
indicated. Because genital ulceration and inflammation may increase the risk of HIV
infection, additional clinical evaluation of PRO 2000/5 gel is warranted, especially for
study participants with active sexual behavior.
Participants apply PRO 2000/5 gel intravaginally either once or twice daily for 14 days. HIV-negative participants in sexually active cohorts (Cohorts A1-A4) are instructed to engage in vaginal intercourse at least twice a week. Participants in the HIV-positive cohort (Cohort B1) abstain from sexual intercourse for the dosing period. Researchers conduct physical exams to see if the gel is having any harmful effects on the woman's vulva, vagina, or cervix. Women and their male partners are questioned about gel usage.
|Ages Eligible for Study:||18 Years to 45 Years|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||Yes|
Volunteers may be eligible for this study if they:
- Are female and 18-45 years of age.
- Are willing and able to complete daily study records.
- Are willing to undergo clinical exams and testing.
- Either have regular menstrual periods or do not menstruate due to use of hormones.
- Agree to stop using female barrier methods of birth control during the study.
- Additionally, volunteers may be eligible for HIV-negative groups in this study if they:
- Have not changed their use of hormonal birth control over the last 3 months.
- Are HIV-negative.
- Have a single male partner at low-risk for HIV infection and agree that he can be asked for his consent.
- Agree to the following: To have vaginal intercourse 2 or more times a week; to use condoms provided by the study for each act of intercourse; to use the gel as directed; not to be in similar studies; not to receive oral sex; not to use IV drugs, except for medical treatment; not to use any other vaginal products; not to douche; and not to use vaginal drying agents.
- Additionally, volunteers may be eligible for the HIV-positive group in this study if they:
- Are HIV-positive.
- Have a CD4 count greater than 200 cells/mm3.
- Have a normal Pap smear at screening.
- Are on stable anti-HIV drug therapy.
- Agree to have no sexual intercourse during the study.
- Have HIV care by qualified medical caregivers.
- Agree to allow study staff access to their HIV medical care information.
- Agree to the following: To use the gel as directed; not to use IV drugs other than for medical treatment; not to use any other vaginal products; not to participate in similar studies; not to receive oral sex; not to douche; and not to use any vaginal drying agents.
- Are menopausal.
- Have certain liver, kidney, or blood problems.
- Have genital problems such as sores.
- Are allergic to anything used in the study, including latex.
- Have used spermicides or condoms treated with spermicides within the week before enrollment.
- Have been in another drug study within the past 30 days.
- Have participated in this trial before and study gel has been permanently discontinued.
- Have had an IUD or begun using hormonal birth control, or had an abnormal Pap smear, a pregnancy, an abortion, gynecologic surgery, breakthrough menstrual bleeding, or vaginal bleeding during or following sexual intercourse, in the last 3 months.
- Have had or received treatment for sexually transmitted diseases in the past 3 months.
- Show signs, on a pelvic exam, indicating a sexually transmitted disease or other genital tract problems.
- Used IV drugs, except for medical reasons, within the past year.
- Received antibiotics in the last 14 days.
- Have had a reaction to an anticoagulant (such as warfarin or heparin).
- Are pregnant or breast-feeding.
- Have a positive urine culture.
Volunteers will not be eligible for this study if they:
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006207
Locations Show More
|United States, North Carolina|
|Research Triangle Park, North Carolina, United States, 27709|
Sponsors and CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)
|Study Chair:||Ken Mayer|
|Study Chair:||Salim Abdool Karim|
|Responsible Party:||National Institute of Allergy and Infectious Diseases (NIAID)|
|ClinicalTrials.gov Identifier:||NCT00006207 History of Changes|
|Other Study ID Numbers:||HIVNET 020|
|Study First Received:||September 11, 2000|
|Last Updated:||July 29, 2008|
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):HIV Seropositivity
Dose-Response Relationship, Drug
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on October 16, 2017
This information is provided by ClinicalTrials.gov.